- SURMOUNT-1 showed average weight loss of 22.5% at the highest dose (15 mg) over 72 weeks
- Head-to-head SURMOUNT-5 trial: Zepbound 20.2% vs Wegovy 13.7% average weight loss
- Tirzepatide works on two hormonal pathways (GLP-1 + GIP), potentially explaining greater efficacy
- SURMOUNT-4 confirms weight regain after stopping — long-term treatment produces best outcomes
- Benefits extend beyond weight: blood pressure, triglycerides, insulin sensitivity, and sleep apnea
SURMOUNT-1: the pivotal trial
The SURMOUNT-1 trial was the first major study of tirzepatide (now branded as Zepbound) for weight management. Published in the New England Journal of Medicine in 2022, it enrolled 2,539 adults with obesity or overweight with at least one weight-related condition but without diabetes.
Results were striking. At 72 weeks, participants on the highest dose (15 mg) lost an average of 22.5% of their body weight — compared to 2.4% in the placebo group. More than one in three participants on the highest dose lost 25% or more of their starting weight.
A 22.5% average weight loss approaches what was previously achievable only through bariatric surgery. This result positioned tirzepatide as the most effective anti-obesity medication studied to date in a randomized controlled trial.
All participants in SURMOUNT-1 also received lifestyle counseling, including reduced-calorie diet guidance and increased physical activity recommendations. The medication was not studied in isolation — it was always part of a broader intervention.
Weight loss by dose: comparing 5 mg, 10 mg, and 15 mg
Tirzepatide is available in three maintenance doses. The SURMOUNT-1 trial tested all three against placebo, providing clear dose-response data.
| Dose | Average weight loss | Patients losing ≥20% |
|---|---|---|
| 5 mg weekly | 16.0% | 32% |
| 10 mg weekly | 21.4% | 46% |
| 15 mg weekly | 22.5% | 57% |
| Placebo | 2.4% | 1.5% |
Even at the lowest dose of 5 mg, weight loss was substantial. However, the 10 mg and 15 mg doses showed meaningfully greater results. Your clinician will determine the appropriate dose based on your response, tolerance, and treatment goals.
SURMOUNT-5: head-to-head against Wegovy
In 2024, results from the SURMOUNT-5 trial provided the first direct comparison between tirzepatide and semaglutide for weight management. This head-to-head study enrolled 751 adults and compared tirzepatide 15 mg to semaglutide 2.4 mg over 72 weeks.
| Medication | Average weight loss | Patients losing ≥15% |
|---|---|---|
| Zepbound (tirzepatide 15 mg) | 20.2% | 71% |
| Wegovy (semaglutide 2.4 mg) | 13.7% | 44% |
Tirzepatide demonstrated statistically greater weight loss at every measured timepoint. However, both medications produced clinically meaningful results, and individual responses varied considerably within each group.
Head-to-head trials compare population averages. Some patients respond better to semaglutide than tirzepatide, and vice versa. The best medication for you depends on your specific health profile, not just average trial results.
How Zepbound works: the dual agonist mechanism
What makes tirzepatide different from semaglutide is its dual mechanism of action. While semaglutide activates only GLP-1 receptors, tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors.
GIP is another incretin hormone produced in the gut after eating. By engaging both receptor pathways, tirzepatide appears to produce more potent effects on appetite regulation, insulin sensitivity, and fat metabolism. This dual action likely explains the greater average weight loss seen in clinical trials.
The dual mechanism does not necessarily mean more side effects. In the SURMOUNT trials, the side effect profile was generally similar to semaglutide — primarily gastrointestinal symptoms during titration that improved over time.
SURMOUNT-2: results in patients with type 2 diabetes
The SURMOUNT-2 trial specifically studied tirzepatide in adults who had both obesity and type 2 diabetes. This population typically loses less weight with anti-obesity medications due to the metabolic effects of diabetes and diabetes medications.
| Dose | Average weight loss | A1C reduction |
|---|---|---|
| 10 mg weekly | 13.4% | -2.1% |
| 15 mg weekly | 15.7% | -2.1% |
| Placebo | 3.3% | -0.5% |
The results were impressive for this population. Many participants achieved both clinically significant weight loss and diabetes remission (defined as A1C below 6.5% without diabetes medication). This dual benefit is particularly relevant for patients managing both conditions.
SURMOUNT-4: long-term maintenance data
The SURMOUNT-4 trial addressed a critical question: what happens when you continue versus stop tirzepatide after initial weight loss? After 36 weeks of open-label treatment (all participants on tirzepatide), patients were randomized to either continue treatment or switch to placebo for an additional 52 weeks.
Patients who continued tirzepatide maintained their weight loss and continued losing. Those who stopped regained most of what they had lost within a year.
Patients who continued tirzepatide lost an additional 5.5% of body weight during the extension period. Those switched to placebo regained 14.0% of body weight. This data strongly supports the concept of obesity as a chronic condition requiring ongoing treatment for sustained benefit.
SURMOUNT-4 reinforces that Zepbound is most effective as a long-term treatment rather than a short-term intervention. At PEAK, we discuss treatment duration expectations from the beginning so patients can plan accordingly.
Weight loss timeline on Zepbound
Like other incretin-based medications, Zepbound uses a gradual dose titration to minimize side effects. Understanding the timeline helps set realistic expectations.
| Timeframe | Typical experience |
|---|---|
| Weeks 1–4 | Starting dose (2.5 mg); mild appetite changes; 2–4 lbs lost; GI adjustment |
| Months 2–3 | Dose increases to 5 mg then 7.5 mg; noticeable appetite reduction; 8–12 lbs cumulative |
| Months 4–6 | Reaching 10–15 mg maintenance dose; steady loss of 4–6 lbs/month |
| Months 6–12 | Peak weight loss phase; most patients reach 15–20% total loss |
| Months 12–18 | Weight loss continues to slow; focus shifts to maintenance and long-term habits |
Late responders: when results take longer
Not everyone responds to Zepbound at the same pace. Some patients see minimal weight loss during the first 12 weeks but then experience significant results as the dose increases. These so-called late responders are not treatment failures — they simply need more time at higher doses.
Research suggests that patients who lose less than 5% of their body weight in the first 12 weeks may still go on to achieve clinically meaningful results by 6–12 months, particularly if they reach the 10 mg or 15 mg dose. Patience and consistent follow-up are essential.
At PEAK, we track progress at regular intervals and adjust treatment plans accordingly. A slow start does not automatically mean the medication is not working — it means the treatment plan may need adjustment.
Health benefits beyond weight loss
Like semaglutide, tirzepatide has demonstrated benefits that extend beyond weight loss alone. In the SURMOUNT trials and related studies, patients experienced improvements in multiple cardiometabolic markers.
- Blood pressure reductions averaging 6–8 mmHg systolic
- Triglyceride reductions of 20–30%
- Improvements in waist circumference and visceral fat
- Improved insulin sensitivity and glycemic control
- Reductions in inflammatory markers (C-reactive protein)
- Improvements in sleep apnea severity (studied in SURMOUNT-OSA)
Weight loss is often the most visible outcome, but the metabolic improvements may be equally or more important for long-term health. These changes reduce the risk of heart disease, stroke, diabetes progression, and other obesity-related conditions.
Important safety information: Zepbound carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
If you are considering Zepbound, the next step is a clinical evaluation to determine whether it is the right fit for your health profile and goals. At PEAK, that conversation happens face to face with a board-certified clinician.
